With its plug-and-play cell therapy platform and complementary bispecific NK cell engagers, Cytovia aims to create both single and combination therapies for cancer treatment. Natural killer (NK ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

The license agreement grants PranaX access to a core patent portfolio covering exosome manufacturing, engineering and therapeutic applications through a technology licensing agreement. This ...

HOUSTON, March 13, 2025 /PRNewswire/ -- PranaX Corporation (www.pranax.com), an emerging regenerative medicine biotechnology company, today announced that it has licensed exosome technology from ...

NEW ORLEANS, March 11, 2025 /PRNewswire/ -- A pioneering Phase 1 clinical trial, reported in a March 9, 2025, ScienceDaily article, is advancing stem cell therapies for Parkinson's disease.

HOUSTON, March 13, 2025 /PRNewswire/ -- PranaX Corporation (www.pranax.com), an emerging regenerative medicine biotechnology company, today announced that it has licensed exosome technology from The ...